Table 4.

Exposure to Erlotinib and OSI-420 in Patients Who Did or Did Not Receive EIAEDs With Erlotinib

Drug or Metabolite Exposure	Treatment Arm
	Erlotinib 150 mg + No EIAED	Erlotinib 300 mg + EIAED
Erlotinib AUCtau, (ng × h)/mL
Cycle 1 day 1	9,790 ± 3,660	9,200 ± 4,880
Cycle 1 day 8	30,200 ± 13,000	13,500 ± 4530
OSI-420 AUC, (ng × h)/mL
Cycle 1 day 1	673 ± 312	1,200 ± 1,080
Cycle 1 day 8	2,680 ± 1,380	1,810 ± 712
Mean OSI-420/erlotinib ratio
Cycle 1 day 1	0.069	0.130
Cycle 1 day 8	0.089	0.134

NOTE. OSI-420 is the main metabolite of erlotinib.

Abbreviations: EIAED, enzyme-inducing anticonvulsant; AUC_tau, area under the plasma concentration-time curve over the dosing interval.